Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

Arcus Biosciences reported Q2 2026 GAAP revenue of $41M and a net loss of $91M ($0.72/share), while lowering collaboration-driven activity expectations tied to the wind-down of domvanalimab; full-year GAAP revenue guidance remains $65M–$75M. The company ended Q2 with $775M in cash and investments (down from $876M) but said it has a cash runway into at least 2H 2028 supported by ~ $600M expected year-end cash/investments. Strategically, it is accelerating casdatifan as its primary growth driver after multiple Phase III domvanalimab trial discontinuations, with PEAK-1 enrollment expected to complete by end-2026 and new ARC-20/PEAK-20 readouts planned for October across >200 patients.

Analysis

RCUS is no longer a multi-asset story; it is now a concentrated HIF-2 bet with enough cash to avoid a near-term financing overhang. That matters because the stock can re-rate on clinical probability, not balance-sheet survival, but it also means every data cut has higher convexity: a clean October package can expand multiples quickly, while a durability miss leaves little else to lean on.

The competitive takeaway is that Merck’s kidney franchise remains the direct loser if Arcus can show sustained target suppression translating into tails on PFS/OS. The more interesting second-order winner is Exelixis: if casdatifan is positioned on top of cabo, cabo becomes an even more entrenched backbone rather than a commodity control, which should support the commercial durability of the regimen even if Arcus captures most of the value. BMS, Summit, and AVEO get inexpensive validation, but their economics are mostly optionality unless the combinations become standards.

The market is likely to overtrade early response metrics in October. For this name, the real signal is whether primary progression is meaningfully lower, whether the curve separates late, and whether prior TKI exposure stops being a drag; those are the mechanisms that justify a $5B-$10B asset, not headline ORR alone. Falsifiers are simple: weak frontline safety, no visible tail advantage versus historical controls, or any suggestion that the late-line advantage disappears in TKI-experienced patients over the next 1-3 months; structurally, anything less than that keeps this in the 'promising but unproven' bucket for 6-18 months.

Key Decisions for Investors

• Buy RCUS on pullbacks into the October investor event as a 1-3 month catalyst trade; size modestly because the setup is binary, but the cash runway through 2H28 lowers dilution risk and supports upside if data are clean.
• Use RCUS Jan-2027 call spreads instead of common if you want defined risk into the frontline readout cycle; the payoff is asymmetric if October data show durable curve separation rather than just early ORR.
• Pair trade idea: long RCUS / short MRK on a small, RCC-specific basis to isolate belzutifan downside risk; thesis breaks if Merck’s broader oncology multiple de-couples from RCC news.
• Do not add aggressively on any post-data spike unless the package shows both lower primary progression and late-tail durability; ORR-only enthusiasm is a trap and would likely be faded within days.
• Set a hard risk checkpoint: if the October dataset does not improve confidence in frontline PFS and late-line OS tail versus existing benchmarks, treat RCUS as a hold, not a high-conviction long.